These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23827313)

  • 1. Generation of a parvovirus B19 vaccine candidate.
    Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
    Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Virus-like Particles of Human Parvovirus B19 with the Internal Location of VP1 Unique Region Produced by
    Shao S; Wang Q; Jin Y; Zhang X; Liu Z; Chen S; Wu H; Yang S; Tang F; Su J; Liang Y; Zhang J; Li Q
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
    Franssila R; Hedman K
    Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease.
    Penkert RR; Young NS; Surman SL; Sealy RE; Rosch J; Dormitzer PR; Settembre EC; Chandramouli S; Wong S; Hankins JS; Hurwitz JL
    Vaccine; 2017 Jun; 35(29):3615-3620. PubMed ID: 28554503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
    Ballou WR; Reed JL; Noble W; Young NS; Koenig S
    J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
    Bostic JR; Brown KE; Young NS; Koenig S
    J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
    Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
    Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate recombinant vaccine for human B19 parvovirus.
    Bansal GP; Hatfield JA; Dunn FE; Kramer AA; Brady F; Riggin CH; Collett MS; Yoshimoto K; Kajigaya S; Young NS
    J Infect Dis; 1993 May; 167(5):1034-44. PubMed ID: 8486937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors.
    Lowin T; Raab U; Schroeder J; Franssila R; Modrow S
    J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):348-52. PubMed ID: 16316399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
    Corcoran A; Mahon BP; Doyle S
    J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
    Suzuki H; Noguchi T; Matsugu N; Suzuki A; Kimura S; Onishi M; Kosaka M; Miyazato P; Morita E; Ebina H
    Vaccine; 2022 Oct; 40(42):6100-6106. PubMed ID: 36114131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19.
    Franssila R; Hokynar K; Hedman K
    J Infect Dis; 2001 Mar; 183(5):805-9. PubMed ID: 11181158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and analysis of polyhistidine-tagged human parvovirus B19 VP1 and VP2 expressed in insect cells.
    Michel PO; Mäkelä AR; Korhonen E; Toivola J; Hedman L; Söderlund-Venermo M; Hedman K; Oker-Blom C
    J Virol Methods; 2008 Sep; 152(1-2):1-5. PubMed ID: 18598721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and immunological relations among human parvovirus B19 genotypes 1 to 3.
    Ekman A; Hokynar K; Kakkola L; Kantola K; Hedman L; Bondén H; Gessner M; Aberham C; Norja P; Miettinen S; Hedman K; Söderlund-Venermo M
    J Virol; 2007 Jul; 81(13):6927-35. PubMed ID: 17409158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans.
    Zuffi E; Manaresi E; Gallinella G; Gentilomi GA; Venturoli S; Zerbini M; Musiani M
    Viral Immunol; 2001; 14(2):151-8. PubMed ID: 11398810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
    Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
    Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goose parvovirus structural proteins expressed by recombinant baculoviruses self-assemble into virus-like particles with strong immunogenicity in goose.
    Ju H; Wei N; Wang Q; Wang C; Jing Z; Guo L; Liu D; Gao M; Ma B; Wang J
    Biochem Biophys Res Commun; 2011 May; 409(1):131-6. PubMed ID: 21554858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
    Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
    J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
    Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
    J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a candidate parvovirus B19 vaccine.
    Bernstein DI; El Sahly HM; Keitel WA; Wolff M; Simone G; Segawa C; Wong S; Shelly D; Young NS; Dempsey W
    Vaccine; 2011 Oct; 29(43):7357-63. PubMed ID: 21807052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.